Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting
Stock Information for Q32 Bio Inc.
Loading
Please wait while we load your information from QuoteMedia.